Sarepta Therapeutics appointed Michael Severino, M.D., chief executive officer and a director, effective July 28, 2026. He succeeds Doug Ingram, whose retirement plan was disclosed on February 25; Ingram will remain an advisor through…
Legend Biotech disclosed that Ying Huang resigned as chief executive officer and a director, effective July 24, after notifying the board on July 22. He is expected to advise the company through August. The…
Tessera Therapeutics appointed Joseph Romanelli as president and chief executive officer, succeeding Michael Severino, who had led the Flagship-founded Gene Writing company since June 2022. Romanelli also joins Tessera’s board and Flagship Pioneering as…
